The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
An analysis using UK Biobank data indicates that the CCR5-Δ32 gene mutations He Jiankui reportedly attempted to introduce into human embryos may be deleterious.
The researchers used circularly permuted Cas9 variants to produce four cytosine and four adenine base editors with an expanded editing window.
With CRISPR being applied to a range of biological problems, researchers are searching for ways to stop its edits, Technology Review reports.
To understand the evolution of brain conditions and other traits, investigators plan to sequence human and pathogen DNA in thousands of samples from Europe.
In Nature this week: analysis of gut microbiome of colorectal cancer patients, enzymes that block CRISPR editing, and more.
Eighteen researchers call for a temporary stop to all clinical uses of human germline editing in a piece appearing in Nature.
The biotech startup, which had been working with Cas12 and Cas13, has now licensed the recently discovered Cas14 protein from UC Berkeley.
CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.